广泛期小细胞肺癌免疫治疗研究进展和展望  

Research progress and prospects on immunotherapy of extensive-stage small cell lung cancer

作　　者：马永春 谢玉瑾 周亚文 马欢 马龙 朱自江 MA Yongchun;XIE Yujin;ZHOU Yawen;MA Huan;MA Long;ZHU Zijiang(Xining First People's Hospital,Qinghai Xining 810000,China;The 4th People's Hospital of Qinghai Province,Qinghai Xining 810000,China;Department of Thoracic Surgery,Gansu Provincial Central Hospital(Gansu Province Maternity and Child Health Hospital),Gansu Lanzhou 730000,China;The 1st School of Clinical Medical,Lanzhou University,Gansu Lanzhou 730000,China)

机构地区：[1]西宁市第一人民医院,青海西宁810000 [2]青海省第四人民医院,青海西宁810000 [3]甘肃省中心医院胸外科(甘肃省妇幼保健院),甘肃兰州730000 [4]兰州大学第一临床医学院,甘肃兰州730000

出　　处：《现代肿瘤医学》2025年第6期1024-1033,共10页Journal of Modern Oncology

基　　金：国家自然科学基金项目(编号:3176050013)。

摘　　要：小细胞肺癌是一种恶性程度高、生长速度快、预后差的恶性肿瘤,约70%的小细胞肺癌患者在初诊时已处于广泛期。长期以来,小细胞肺癌的治疗方案一直停滞不前,近些年,免疫治疗在小细胞肺癌中有了突破性进展,部分免疫检查点抑制剂的临床试验已经证实在小细胞肺癌方面的有效性及安全性,该文将对程序性死亡蛋白-1(PD-1)/程序性死亡配体-1(PD-L1)抑制剂和细胞毒性T淋巴细胞抗原-4(CTLA-4)抑制剂治疗广泛期小细胞肺癌的临床研究进展进行综述。Small cell lung cancer is a malignant tumor with high degree of malignancy,fast growth rate and poor prognosis.About 70%of patients with small cell lung cancer have been in the extensive stage at the first diagnosis.For a long time,the treatment of small cell lung cancer has been stagnant.In recent years,immunotherapy has made new breakthroughs in small cell lung cancer.Clinical trials of some immune checkpoint inhibitors have confirmed the effectiveness and safety of small cell lung cancer.This article reviews the clinical progress of programmed death protein-1(PD-1)/programmed death ligand-1(PD-L1)inhibitors and cytotoxic T lymphocyte antigen-4(CTLA-4)inhibitors in the treatment of extensive-stage small cell lung cancer.

关 键 词：广泛期小细胞肺癌 免疫治疗 研究进展 

分 类 号：R734.2[医药卫生—肿瘤]